Your browser doesn't support javascript.
loading
HIF-mediated Suppression of DEPTOR Confers Resistance to mTOR Kinase Inhibition in Renal Cancer.
Doan, Hong; Parsons, Alexander; Devkumar, Shruthi; Selvarajah, Jogitha; Miralles, Francesc; Carroll, Veronica A.
Afiliação
  • Doan H; Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's, University of London, London SW17 0RE, UK.
  • Parsons A; Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's, University of London, London SW17 0RE, UK.
  • Devkumar S; Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's, University of London, London SW17 0RE, UK; Centre for Biomedical Education, Institute of Medical and Biomedical Education, St George's, University of London, London SW17 0RE, UK.
  • Selvarajah J; Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's, University of London, London SW17 0RE, UK; Centre for Biomedical Education, Institute of Medical and Biomedical Education, St George's, University of London, London SW17 0RE, UK.
  • Miralles F; Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's, University of London, London SW17 0RE, UK; Centre for Biomedical Education, Institute of Medical and Biomedical Education, St George's, University of London, London SW17 0RE, UK.
  • Carroll VA; Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's, University of London, London SW17 0RE, UK; Centre for Biomedical Education, Institute of Medical and Biomedical Education, St George's, University of London, London SW17 0RE, UK. Electronic address: vc
iScience ; 21: 509-520, 2019 Nov 22.
Article em En | MEDLINE | ID: mdl-31710966
Mechanistic target of rapamycin (mTOR) is a fundamental regulator of cell growth, proliferation, and metabolism. mTOR is activated in renal cancer and accelerates tumor progression. Here, we report that the mTOR inhibitor, DEP domain-containing mTOR-interacting protein (DEPTOR), is strikingly suppressed in clear cell renal cell carcinoma (ccRCC) tumors and cell lines. We demonstrate that DEPTOR is repressed by both hypoxia-inducible factors, HIF-1 and HIF-2, which occurs through activation of the HIF-target gene and transcriptional repressor, BHLHe40/DEC1/Stra13. Restoration of DEPTOR- and CRISPR/Cas9-mediated knockout experiments demonstrate that DEPTOR is growth inhibitory in ccRCC. Furthermore, loss of DEPTOR confers resistance to second-generation mTOR kinase inhibitors through deregulated mTORC1 feedback to IRS-2/PI3K/Akt. This work reveals a hitherto unknown mechanism of resistance to mTOR kinase targeted therapy that is mediated by HIF-dependent reprograming of mTOR/DEPTOR networks and suggests that restoration of DEPTOR in ccRCC will confer sensitivity to mTOR kinase therapeutics.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: IScience Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: IScience Ano de publicação: 2019 Tipo de documento: Article